Declines in human papillomavirus (HPV)-Associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, United States, 2008-2015

Clinical Infectious Diseases

Volumn 65, Issue 6, 2017, Pages 884-889

  Niccolai, Linda M ^a,b   Meek, James I ^a,b   Brackney, Monica ^a,b   Hadler, James L ^a,b   Sosa, Lynn E ^c   Weinberger, Daniel M ^b  

^a Connecticut Emerging Infections Program at Yale ^*  (United States)

^b YALE UNIVERSITY   (United States)

^c CDC   (United States)

Author keywords

Cervical lesions; Human papillomavirus; Surveillance; Vaccination; Vaccine impact

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; BEHAVIOR CHANGE; CANCER EPIDEMIOLOGY; CANCER SCREENING; CHLAMYDIA TRACHOMATIS; CONNECTICUT; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MANDATORY REPORTING; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RISK FACTOR; SEXUAL BEHAVIOR; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; YOUNG ADULT; ADENOCARCINOMA IN SITU; CHLAMYDIASIS; EARLY CANCER DIAGNOSIS; INCIDENCE; STATISTICS AND NUMERICAL DATA; TRENDS; UNSAFE SEX; UTERINE CERVIX TUMOR; VACCINATION COVERAGE; VIROLOGY;

ADENOCARCINOMA IN SITU; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CONNECTICUT; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRUS VACCINES; UNSAFE SEX; UTERINE CERVICAL NEOPLASMS; VACCINATION COVERAGE; YOUNG ADULT;

EID: 85031897552     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix455     Document Type: Article

References (24)

1. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010; 28:4731-7.
2. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-Analysis. Lancet Infect Dis 2015; 15:565-80.
3. Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013; 53:679-82.
4. Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: A systematic review. Adv Ther 2015; 32:10-30.
5. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus- related disease. Am J Obstet Gynecol 2004; 191:114-20.
6. Rogstad KE. The psychological impact of abnormal cytology and colposcopy. BJOG 2002; 109:364-8.
7. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer S. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106:djt460.
8. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348:g1458.
9. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study. BMC Med 2013; 11:227.
10. Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol 2014. doi:10.1200/JCO.2013.52.4645.
11. Pollock KG, Kavanagh K, Potts A, et al. Reduction of low-And high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111:1824-30.
12. Lipsitch M, Jha A, Simonsen L. Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies. Int J Epidemiol 2016. doi:10.1093/ije/dyw124.
13. Centers for Disease Control and Prevention. Cervical cancer screening guidelines for average-risk women. Available at: http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf. Accessed 30 November 2015.
14. Centers for Disease Control and Prevention. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years -United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:784-92.
15. Niccolai LM, Julian PJ, Bilinski A, et al. Area-based poverty, racial, and ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009. Am J Public Health 2013; 103:156-63.
16. Niccolai LM, Julian P, Meek J, McBride V, Hadler J, Sosa L. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarker Prev 2013; 22:1446-50.
17. Pingali SC, Warren JL, Mead AM, Sharova N, Petit S, Weinberger DM. Association between local pediatric vaccination rates and patterns of pneumococcal disease in adults. J Infect Dis 2015. doi:10.1093/infdis/jiv431.
18. Flagg EW, Torrone EA, Weinstock H. Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007- 2014. Am J Public Health 2016; 106: 2211-8.
19. Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol 2016. doi:10.1001/jamaoncol.2016.3609.
20. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014; 25:915-22.
21. Baldur-Felskov B, Munk C, Nielsen TSS, et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012. Cancer Causes Control 2015. doi:10.1007/s10552-015-0603-7.
22. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet 2011; 377:2085-92.
23. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2014. Atlanta, GA: CDC, 2015.
24. Hariri S, Johnson ML, Bennett NM, et al; HPV-IMPACT Working Group. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 2015; 121:2775-81.